Clinical and Immunomodulatory Effects of Toceranib Combined with Low‐Dose Cyclophosphamide in Dogs with Cancer

Journal of Veterinary Internal Medicine

L. Mitchell¹  D.H. Thamm¹ 

[1]Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO

关键词: Metronomic;    Neoplasia;    Regulatory T cell;    Tyrosine kinase inhibitor;   

DOI  :  10.1111/j.1939-1676.2011.00883.x

来源: Wiley

【 摘 要 】

Abstract

Background

Tyrosine kinase inhibitors (TKIs) and metronomic dosing of cyclophosphamide (CYC) can improve tumor control by suppression of regulatory T cells (Treg) and restoration of T cell-mediated immune responses in mice and humans. The immunomodulatory effects of the TKI toceranib, as a single agent or in combination with metronomic CYC, have not been previously investigated in dogs.

Hypothesis

The primary objectives of this study were to determine the effects of toceranib and metronomic CYC treatment on lymphocyte subsets including Treg and on interferon-gamma (IFN-γ) secretion in dogs with cancer. We hypothesized that toceranib would selectively decrease Treg numbers and increase IFN-γ production and that addition of CYC would further enhance these effects.

Animals

Fifteen client-owned dogs with advanced tumors were entered into a prospective clinical trial.

Methods

Dogs received toceranib at 2.75 mg/kg once every other day. After 2 weeks, oral CYC was added at 15 mg/m² daily. Numbers of Treg and lymphocyte subsets were measured in blood by flow cytometry during the 8-week study period. Serum concentrations of IFN-γ were measured by ELISA.

Results

Administration of toceranib significantly decreased the number and percentage of Treg in the peripheral blood of dogs with cancer. Dogs receiving toceranib and CYC demonstrated a significant increase in serum concentrations of IFN-γ, which was inversely correlated with Treg numbers after 6 weeks of combination treatment.

Conclusions

In addition to antitumor effects, these data support further investigations into the immunomodulatory effects of toceranib, administered alone or in combination with CYC in dogs with cancer.

【 授权许可】

Unknown   
Copyright © 2012 by the American College of Veterinary Internal Medicine